MedWatch

Bank says Demant prognosis probably affected by component shortages

Uncertainties about the lack of components and transportation as well as increased investments are contributing factors dampening the profit outlook for Demant’s 2022, says analyst at Danish bank Sydbank.

Photo: Demant / PR

Demant has released its expectations for 2022, including an organic growth of 5–9 percent and an EBIT result of DKK 3.4–3.7bn (USD 521–567m), in connection with the full-year financial figures for 2021 on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs